Adjunct to diet & exercise for the treatment of adults w/ insufficiently controlled type 2 DM, as monotherapy when metformin is considered inappropriate due to intolerance or contraindications, or in addition to other medicinal products for the treatment of diabetes.
SC Initially 0.25 mg once wkly. After 4 wk, increase dose to 0.5 mg once wkly. After at least 4 wk w/ 0.5 mg once wkly, dose can be increased to 1 mg once wkly to further improve glycaemic control.
Wkly doses >1 mg are not recommended. Do not administer by IV or IM. Do not use in patients w/ type 1 DM or for the treatment of diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients w/ CHF NYHA class IV. May be associated w/ GI adverse reactions. Risk of acute pancreatitis. Increased risk of hypoglycaemia in combination w/ a sulfonylurea or insulin. Increased risk of developing diabetic retinopathy complications in patients w/ diabetic retinopathy treated w/ insulin & semaglutide. Not recommended in patients w/ ESRD. Caution in patients w/ severe hepatic impairment. Women of childbearing potential are recommended to use contraception while on treatment. Should not be used during pregnancy & breast-feeding. Discontinue treatment at least 2 mth before a planned pregnancy. Safety & efficacy in childn & adolescents <18 yr have not been established.
Sign Out
